trending Market Intelligence /marketintelligence/en/news-insights/trending/5SBK74hGo34Zhvv03KpAIw2 content esgSubNav
In This List

Designations for Alnylam Pharmaceuticals, Provention Bio

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Designations for Alnylam Pharmaceuticals, Provention Bio

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Aug. 9.

Complete response letters

* Kala Pharmaceuticals Inc.'s KPI-121 0.25% therapy to treat symptoms of dry eye disease.

Extended review

* Intra-Cellular Therapies Inc.'s lumateperone for schizophrenia. The FDA classified the New York-based company's planned submission of additional information as a major amendment to its application.

* Avadel Pharmaceuticals PLC's injectable hospital product candidate AV001 for an undisclosed indication. Dublin-based Avadel said it submitted additional information requested by the FDA which was considered by the regulator as a major amendment to the company's application.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: Associated Press

Priority review

* Alnylam Pharmaceuticals Inc.'s givosiran for acute hepatic porphyria. The FDA said efficacy data from an additional clinical trial will be needed to support resubmission of the application.

Breakthrough therapy

* Provention Bio Inc.'s PRV-031 for preventing and delaying type 1 diabetes.